LL-37 Peptide (5mg)

$50.58

LL-37 peptide is a 37-amino acid peptide derived from the C-terminal part of the human cathelicidin protein (hCAP-18). It has broad antimicrobial activity against bacteria (both Gram-positive and Gram-negative), fungi, and some viruses.

LL-37 Peptide (CAP-18)

LL-37 peptide is a multifunctional antimicrobial peptide that serves as a critical component of the innate immune system. Derived from the C-terminal end of the human cathelicidin protein hCAP-18, this 37-amino acid peptide is produced by various cell types including neutrophils, macrophages, and epithelial cells.

Beyond its direct antimicrobial activities against bacteria, viruses, and fungi, LL-37 peptide exhibits remarkable immunomodulatory functions such as chemotaxis, wound healing promotion, and inflammation regulation. It achieves this versatility by interacting with cell membranes and various receptors, modifying immune cell responses.

Due to its therapeutic potential, LL-37 peptide has become a significant focus in research for developing novel antimicrobial agents, particularly against antibiotic-resistant pathogens, as well as treatments for inflammatory conditions and wound management.

Peptide Information

Property	Value
Peptide Sequence	Leu-Leu-Gly-Asp-Phe-Phe-Arg-Lys-Ser-Lys-Glu-Lys-Ile-Gly-Lys-Glu-Phe-Lys-Arg-Ile-Val-Gln-Arg-Ile-Lys-Asp-Phe-Leu-Arg-Asn-Leu-Val-Pro-Arg-Thr-Glu-Ser
Molecular Formula	C205H340N60O53
Molecular Weight	4493 g/mol
CAS Number	154947-66-7
PubChem CID	16198951
Synonyms	CAP-18, Cathelicidin, antibacterial peptide LL-37, 154947-66-7, ropocamptide

LL-37 Peptide Benefits

Broad-Spectrum Antimicrobial Activity: Directly kills Gram-positive and Gram-negative bacteria, fungi, and certain enveloped viruses by targeting and disrupting their cell membranes.
Neutralization of Endotoxins: Binds directly to bacterial lipopolysaccharides (LPS), preventing LPS-induced septic shock and dampening hyper-inflammatory signaling.
Immune Recruitment (Chemotaxis): Recruits neutrophils, monocytes, and T-cells to infection or tissue injury sites.
Wound Healing & Angiogenesis: Stimulates vascular endothelial growth factor (VEGF) expression, promoting new blood vessel growth and epithelial tissue repair.

Medical & Pathological Relevance

Condition / Context	Role of LL-37
Psoriasis	Overexpressed: Binds self-DNA/RNA released from dead cells, triggering autoimmune dendritic cell activation.
Atopic Dermatitis	Underexpressed: Low levels contribute to frequent secondary bacterial infections (Staphylococcus aureus).
Rosacea	Abnormal Processing: Cleaved into shorter, aberrant forms that induce facial redness and inflammation.
Drug Development	Therapeutic Potential: Under research for bio-coatings, chronic wound dressings, and novel treatments targeting multidrug-resistant pathogens.

Clinical Dosage & Administration Context

Note: There is no standardized, FDA-approved human dosage protocol for general wellness or systemic use. Clinical studies have primarily tested topical formulations for hard-to-heal chronic wounds:

Topical Wound Application (Clinical Trial Data):
- In clinical trials for chronic venous leg ulcers and large wounds, topical LL-37 peptide solutions were applied twice weekly.
- Effective Concentrations: $0.5\text{ mg/mL}$ and $1.6\text{ mg/mL}$ significantly accelerated wound closure and re-epithelialization.
- U-Shaped Dose Curve / Toxicity Threshold: High topical doses ( $3.2\text{ mg/mL}$ ) lost therapeutic efficacy and caused localized adverse reactions, such as tissue irritation or necrosis.
Anecdotal / Off-Label Subcutaneous Use: While underground or peptide wellness communities sometimes use $100\text{ mcg}$ – $250\text{ mcg}$ daily via subcutaneous injection, these protocols are strictly experimental and lack rigorous human safety data.